Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

@article{Santin2008TrastuzumabTI,
  title={Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu},
  author={A. Santin and S. Bellone and J. Roman and J. McKenney and S. Pecorelli},
  journal={International Journal of Gynecology & Obstetrics},
  year={2008},
  volume={102}
}
  • A. Santin, S. Bellone, +2 authors S. Pecorelli
  • Published 2008
  • Medicine
  • International Journal of Gynecology & Obstetrics
    • To study the effect of trastuzumab in patients with progressive or recurrent metastatic endometrial carcinoma shown by immunohistochemistry to overexpress the HER2/neu receptor. 
    View on Wiley
    ncbi.nlm.nih.gov
    167 Citations
    Highly Influencial Citations
    3
    Background Citations
    54
    Methods Citations
    1
    Results Citations
    2
    167 Citations
    Citation Type

    Citation Type

    Her-2 targeting in uterine papillary serous carcinoma.
    • 8
    HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in‐situ hybridisation
    • 6
    • Highly Influenced
    • PDF
    HER 2 EXPRESSION IN RENAL CELL CARCINOMA
    • PDF
    Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma
    • 3
    Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors
    • 6
    Correlation of HER-2 over expression and tumour grade in ductal carcinoma breast : A three years study in a tertiary teaching hospital in Uttar Pradesh , India
    • Dr. Shailza, Dr. Alok Mohan
    • 2015
    HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
    • 82
    Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option
    • 10
    • Highly Influenced
    Targeted therapy for high-risk endometrial carcinoma
    Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
    • 226

    References

    SHOWING 1-10 OF 13 REFERENCES
    Use of trastuzumab in the treatment of metastatic endometrial cancer
    • 66
    HER‐2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
    • 112
    Trastuzumab: Targeted Therapy for the Management of HER-2/neu-Overexpressing Metastatic Breast Cancer
    • L. Emens
    • Medicine
    • American journal of therapeutics
    • 2005
    • 100
    Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
    • 106
    Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
    • 44
    Two pathogenetic types of endometrial carcinoma.
    • 1,666
    Untangling the ErbB signalling network
    • 5,941
    • PDF
    Cancer Statistics, 2006
    • 5,254
    DH,HibshooshH,HershmanD.Her2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
    • Int J Gynecol Cancer
    • 2006
    SmithDH,HibshooshH,HershmanD.Her2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
    • Int J Gynecol Cancer
    • 2006